In the management of dengue-induced thrombocytopenia, a narrative review suggested the use of thrombopoietin receptor (TPO-R) agonists, such as eltrombopag and romiplostim, the latter approved by the FDA in 2018 for idiopathic thrombocytopenia [239]. The gene discussed is MPL; the disease is dengue disease.